Ken Griffin Eagle Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.71 - $6.07 $371 - $607	100 New	100 $0
Q1 2024 May 15, 2024	BUY	$4.26 - $6.51 $3,834 - $5,859	900 Added 17.65%	6,000 $31,000
Q4 2023 Feb 14, 2024	BUY	$4.63 - $15.21 $17,594 - $57,798	3,800 Added 292.31%	5,100 $26,000
Q3 2023 Nov 14, 2023	BUY	$15.21 - $22.88 $12,168 - $18,304	800 Added 160.0%	1,300 $20,000
Q2 2023 Aug 14, 2023	SELL	$17.74 - $31.87 $5,321 - $9,561	-300 Reduced 37.5%	500 $9,000
Q1 2023 May 15, 2023	BUY	$25.06 - $34.09 $7,518 - $10,227	300 Added 60.0%	800 $22,000
Q4 2022 Feb 14, 2023	BUY	$24.98 - $39.77 $12,490 - $19,885	500 New	500 $14,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $6.77M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.